Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice
Authors:
- Axel SemjonowASAxel Semjonow
- Paul E.C. SibleyPSPaul E.C. Sibley
- Rolf LamerzRLRolf Lamerz
- Per Hyltoft PetersenPPPer Hyltoft Petersen
- Walter AlbrechtWAWalter Albrecht
- Peter BialkPBPeter Bialk
- Massimo GionMGMassimo Gion
- Frank JunkerFJFrank Junker
- Hans-Peter SchmidHSHans-Peter Schmid
- Hein Van PoppelHPHein Van Poppel
- 1 August 2005
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (8) , 1342-1351
Abstract
Background: The objectives of this study were to determine whether a single result for total prostate-specific antigen (tPSA) can be used confidently to guide the need for prostate biopsy and by how much serial tPSA measurements must differ to be significant. tPSA measurements include both analytical and biological components of variation. The European Group on Tumor Markers conducted a literature survey to determine both the magnitude and impact of biological variation on single, the mean of replicate, and serial tPSA measurements. Methods: The survey yielded 27 studies addressing the topic, and estimates for the biological variation of tPSA could be derived from 12 of these studies. Results: The mean biological variation was 20% in the concentration range 0.1–20 μg/L for men over 50 years. The biological variation means that the one-sided 95% confidence interval (CI) of the dispersion for a single tPSA result is ∼33%. Three replicate samples with one analysis on each narrow the one-sided 95% CI for the mean concentration to ∼20% and facilitate decisions on prostate biopsy. During monitoring of serial measurements, the change needed for significance is ∼50% (P Conclusions: The biological variation of tPSA has implications for screening, diagnosis, and monitoring. Single measurements may not be sufficiently precise for screening and diagnosis. Replicate samples and calculation of the mean concentration may improve precision by reducing the dispersion. Monitoring of tPSA requires an estimate of either the change needed for significance or, alternatively, of the significance of the change.Keywords
This publication has 56 references indexed in Scilit:
- Intra‐individual variation of serum prostate specific antigen levels in men with benign prostate biopsiesBJU International, 2004
- Effect of Verification Bias on Screening for Prostate Cancer by Measurement of Prostate-Specific AntigenNew England Journal of Medicine, 2003
- PROSTATE SPECIFIC ANTIGEN VARIATION IN PATIENTS WITHOUT CLINICALLY EVIDENT PROSTATE CANCERJournal of Urology, 1999
- Assessment of Biological Variation and Analytical Imprecision of CA 125, CEA, and TPA in Relation to Monitoring of Ovarian CancerGynecologic Oncology, 1999
- Biological Variation of Total, Free and Percent Free Serum Prostate Specific Antigen Levels in Screening VolunteersJournal of Urology, 1997
- Effect of Digital Rectal Examination and Needle Biopsy on Serum Total and Percentage of Free Prostate Specific Antigen LevelsJournal of Urology, 1997
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor MarkersJNCI: Journal of the National Cancer Institute, 1996
- Physiological Variation of Serum Prostate Specific Antigen in the 4.0 to 10.0 ng./ml. Range in Male VolunteersJournal of Urology, 1996
- Pitfalls in Interpreting Prostate Specific Antigen VelocityJournal of Urology, 1996
- Using Repeated Measures of Symptom Score, Uroflowmetry and Prostate Specific Antigen in the Clinical Management of Prostate DiseaseJournal of Urology, 1995